Navigation Links
Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event

KANSAS CITY, Kan., Aug. 29, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it will host a Pet Therapeutics Primer and Product Update Event, to be held September 11, 2013, at the Four Seasons Hotel in Boston. 

The purpose of the event is to comprehensively lay out the pet therapeutics regulatory framework and to provide a detailed program-by-program update on Aratana's current pet therapeutic development programs.Event:Pet Therapeutics Primer & Product UpdateDate: Wednesday, September 11, 2013 Time: 6:00 – 7:30 p.m. (Eastern Time) Location:Parris Room; Four Seasons Hotel BostonThe event will be webcast live beginning with the company presentations at 6:30 p.m. Eastern Time, and will then be made available as an archive on the Aratana Therapeutics website at

Program Agenda:
Dr. Steven St. Peter, President and Chief Executive Officer of Aratana Therapeutics, will provide a brief introduction to the Company and its pipeline of pet therapeutic product candidates.  He also will discuss Aratana's licensing and partnership strategy for expanding its development pipeline.

Dr. Linda Rhodes, Aratana's Chief Scientific Officer, will provide an overview of the regulatory framework at the FDA's Center for Veterinary Medicine; specifically, the three concurrent regulatory work-streams: safety, efficacy and manufacturing.  Dr. Rhodes also will discuss the mechanics of filing an administrative New Animal Drug Application (NADA) and the subsequent notification of approval. 

Dr. Ernst Heinen, Aratana's Head of Drug Development and Evaluation, will provide an in-depth development update for each of Aratana's current product candidates, each of which is being developed concurrently for both cats and dogs.  These include AT-001, the Company's EP4 antagonist for the treatment of pain; AT-002, its ghrelin agonist for treating inappetence; and AT-003, Aratana's liposomal bupivacaine injection for treating post-operative pain.

There will be an opportunity for Q&A after each session, during which Dr. Marie-Paul Lachaud, Aratana's Head of Drug Development in Europe; Tammy Newbold, Aratana's Vice President of Chemistry, Manufacturing and Controls; and Don Stitzenberg, Aratana's Vice President of Manufacturing, will also be available.

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors); (212) 375-2664Andrew Mielach (media); (212) 375-2694

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
6. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
7. Aratana to Participate in Leerink Swanns November Management Access Days
8. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
9. Echo Therapeutics Announces Management Changes
10. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
11. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO ... guidance technology at the Radiological Society of ... Chicago November 29 – ... is designed to offer customers unrivaled versatility, enhanced ... --> ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
Breaking Medicine News(10 mins):